Want to see SE:MAGLE full AI Analyst Report?
Top Page
Magle Chemoswed Holding AB
(MAGLE)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr0.41
▼(-97.60% Downside)
Action:Upgraded
Date:08/19/26
The score is primarily weighed down by weakened financial performance—sharp profitability decline, sustained cash burn, and higher leverage—alongside a pronounced technical downtrend (price below all major moving averages with negative MACD). Valuation is difficult to assess due to negative earnings and no stated dividend yield, providing limited offset.
Positive Factors
Revenue Growth
Positive TTM revenue growth indicates continued demand for the company’s pharmaceutical development, manufacturing, and related services. Sustained top-line expansion can improve operating leverage if growth continues and the current cost base is better controlled.
Negative Factors
Severe Profitability Decline
The sharp shift from prior profitable years to a deeply negative net margin indicates that the current cost structure is overwhelming gross profit. Persistent losses could restrict reinvestment, weaken equity, and make the revenue growth trend less valuable to shareholders.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Positive TTM revenue growth indicates continued demand for the company’s pharmaceutical development, manufacturing, and related services. Sustained top-line expansion can improve operating leverage if growth continues and the current cost base is better controlled.
Read all positive factors
Magle Chemoswed Holding AB (MAGLE) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr12.71M
Dividend YieldN/A
Average Volume (3M)1.06K
Price to Earnings (P/E)―
Beta (1Y)0.15
Revenue Growth1.80%
EPS Growth-1367.42%
CountrySE
Employees150
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.23
Shares Outstanding30,263,191
10 Day Avg. Volume1,291
30 Day Avg. Volume1,058
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.92
Price to Sales (P/S)1.28
P/FCF Ratio-8.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.4
Revenue Forecast (FY)kr285.10M
Magle Chemoswed Holding AB Business Overview & Revenue Model
Company Description
Magle Chemoswed Holding AB (publ), based in Malmö, Sweden, specializes in the research, development, and manufacturing of products within the pharmaceutical chemistry and technology sectors. The company's core activities include the process develo...
How the Company Makes Money
null...
Magle Chemoswed Holding AB Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
38
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 290.72M | 282.92M | 236.04M | 170.44M | 145.68M | 132.15M |
| Gross Profit | 158.08M | 232.43M | 221.55M | 152.87M | 134.38M | 110.83M |
| EBITDA | -31.06M | -24.25M | 59.21M | 31.40M | 25.77M | 18.14M |
| Net Income | -169.90M | -159.88M | 11.94M | 12.17M | 9.14M | 4.28M |
Balance Sheet | ||||||
| Total Assets | 813.22M | 911.03M | 1.09B | 272.97M | 252.86M | 237.18M |
| Cash, Cash Equivalents and Short-Term Investments | 2.08M | 13.59M | 2.72M | 7.08M | 9.88M | 3.98M |
| Total Debt | 343.99M | 346.19M | 359.92M | 60.30M | 50.34M | 36.46M |
| Total Liabilities | 552.80M | 515.19M | 531.58M | 114.75M | 106.09M | 98.39M |
| Stockholders Equity | 260.41M | 395.84M | 560.60M | 158.22M | 146.77M | 138.79M |
Cash Flow | ||||||
| Free Cash Flow | -111.10M | -44.52M | -27.85M | 209.00K | -4.41M | 14.21M |
| Operating Cash Flow | -109.79M | -31.93M | -11.70M | 15.33M | 12.47M | 26.04M |
| Investing Cash Flow | -1.47M | -12.59M | -9.97M | -20.41M | -21.49M | -34.05M |
| Financing Cash Flow | 107.32M | 55.45M | 17.09M | 2.52M | 14.80M | 5.87M |
Magle Chemoswed Holding AB Technical Analysis
Negative
17.20
Price Trends
0.85
Negative
2.38
Negative
8.03
Negative
Market Momentum
-0.17
Negative
28.90
Positive
10.26
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MAGLE, the sentiment is Negative. The current price of 17.2 is above the 20-day moving average (MA) of 0.48, above the 50-day MA of 0.85, and above the 200-day MA of 8.03, indicating a bearish trend. The MACD of -0.17 indicates Negative momentum. The RSI at 28.90 is Positive, neither overbought nor oversold. The STOCH value of 10.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:MAGLE.
Magle Chemoswed Holding AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | kr588.70M | 3.07 | 77.69% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr91.41M | -2.43 | -120.70% | ― | -97.37% | 25.28% | |
47 Neutral | kr78.91M | -14.45 | -190.99% | ― | 22.42% | 30.55% | |
44 Neutral | kr1.59B | -4.75 | -53.88% | ― | 258.30% | 28.33% | |
42 Neutral | kr12.71M | -0.05 | -41.63% | ― | 1.80% | -1367.42% | |
42 Neutral | kr172.85M | -8.93 | -56.67% | ― | ― | 43.32% |
* Healthcare Sector Average
SE:MAGLE
Magle Chemoswed Holding AB
0.42
-22.78
-98.19%
SE:BINV
BioInvent International AB
24.20
-11.95
-33.06%
SE:NEEMS.B
Scandinavian ChemoTech AB Class B
3.01
-0.16
-5.05%
SE:ELIC
Elicera Therapeutics AB
2.59
-4.27
-62.24%
SE:SPAGO
Spago Nanomedical AB
0.11
-0.08
-40.63%
SE:CANTA
Cantargia AB
2.09
-0.54
-20.61%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.